| |
|
|
| |
|
|
| |
Holly Jane Meany, MD
|
|
 |
Center of Excellence, Departments, and Programs
The Center for Cancer and Blood Disorders
Oncology
Solid Tumor Program
Specialties: Neuroblastoma , Germ Cell Tumors , Rhabdomyosarcoma
|
|
| Board Certifications |
American Board of Pediatrics
American Board of Pediatrics/Hematology-Oncology
|
National Provider Identifier
 |
1194810325 |
|
| Practice Locations |
Children's National Medical Center - Main Hospital
111 Michigan Avenue, NW
Washington, DC
Phone: 202-476-5000
 
|
|
| Biography |
Holly Jane Meany, MD, is a pediatric oncologist at Children's National. She is a member of the Solid Tumor Program.
Dr. Meany's clinical research is focused on phase I clinical trials and pharmacology in the development of new agents for treating pediatric cancers. |
|
| Education |
| Type | School | Location | Degree | Field of Study | Years | | Undergraduate Education | College of William and Mary | Williamsburg, VA | Bachelor of Science | | 1991 -1995 | | Medical School | Ohio State University College of Medicine | Columbus, OH | Doctor of Medicine | | 1996 -2000 |
|
|
| Training |
| Type | Institution | Location | Position | Specialty | Years | | Internship Program | Children's Hospital of Columbus | Columbus, OH | Intern | | 2000 - 2001 | | Residency Program | Children's Hospital of Columbus | Columbus, OH | Resident | | 2001 - 2003 | | Fellowship Program | Children's National Medical Center | Washington, DC | Fellow | | 2003 - 2006 |
|
|
| National and International Recognition |
| Award | Institution | Event | Year | | Career Development Award | American Society of Clinical Oncology | | 2009 | | The Young Investigators Award | American Society of Clincial Oncology | | 2006 | | Janet M Glasgow Memorial Award | American Medical Women’s Association | | | | | | | | | | |
|
|
| Affiliations and Memberships |
| Title | Institution | Committee / Section | Years | | Member | | American Society of Hematology | | | Member | | American Society of Clinical Oncology | | | Member | | Children's Oncology Group | |
|
|
| Publications |
Journal Article, Meany, H.J., Warren, K.E., Fox, E., et al (2009), Pharmacokinetics of temozolomide administered in combination with O(6)-benzylguanine in children and adolescents with refractory solid tumors, Cancer Chemotherapy Pharmacology.
Journal Article, Aikin, A., Balis, F.M., Fox, E., Meany, H.J., Murphy, R.F., Whitcomb, P., Widemann, B.C. (2008), Pediatric Phase I Trial Design Using a Pharmacodynamic Marker as the Primary Endpoint, Journal of Clinical Oncology.
Journal Article, Finklestein, J.Z., Kelleher, J., Meany, H.J., Reaman, G., Sato, J., Seibel, N.L., Sondel, P., Sun, J. (2008), Phase 2 Trial of Recombinant Tumor Necrosis Factor-alpha in Combination With Dactinomycin in Children With Recurrent Wilms Tumor, Journal of Immunotherapy, 0.
Journal Article, Balis, F.M., Fox, E., McCully, C., Meany, H.J., Tucker, C. (2007), The Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite (OSI-420) After Intravenous Administration of Erlotinib in Non-human Primates , Cancer Chemotherapy and Pharmacology.
Journal Article, Gidvani, V.K., Meany, H.J., Minniti, C.P. (2007), Utility of PET Scan to Predict Relapse in Pediatric Patients with Hodgkin’s Disease, Pediatric Blood & Cancer, 48, 4 , 399-402.
Journal Article, Meany, H.J., Fox, E., Hagey, A.E., et.al (2006), In vitro cytotoxicity of ABT-751, a novel tubulin inhibitor, in pediatric solid tumor cell lines, Proceedings of the American Association for Cancer Research.
Journal Article, Chen, K., Crosby, M.G., Heritage, D.W., Jahn, J., Leitenberg, D., Meany, H., Meloni-Ehrig, A.M., Mowrey ,P.N., Scheerle, J., Seibel, N., Suchan, S., Tirado, C.A. (2005), Isolated del(14)(q21) in a Case of Precursor B-cell Acute Lymphoblastic Leukemia, Cancer Genetics and Cytogenetics, 161, 82-85.
For a more comprehensive list of publications for Holly Meany, MD view the National Library of Medicine’s PubMed online database |
|
|
|
|
|
|
